Does Dr. STEPHANIE BERNSTEIN have financial conflicts of interest?

Dr. STEPHANIE BERNSTEIN (MD) has received a total of $505,490 in pharmaceutical and medical device industry funding between 2021 and 2024. This includes $340,260 in personal promotional payouts (consulting, meals, travel) and $165,230 in clinical research grants. Financial ties do not automatically imply conflict of interest, but are disclosed under the Sunshine Act.

Which pharmaceutical companies pay Dr. STEPHANIE BERNSTEIN?

According to CMS Open Payments data, Dr. STEPHANIE BERNSTEIN received funding from ACERTA PHARMA ($224,305), JANSSEN RESEARCH & DEVELOPMENT ($104,045), and ASTRAZENECA UK LIMITED ($99,715).

Does Dr. STEPHANIE BERNSTEIN receive research grants or speaking fees?

Dr. STEPHANIE BERNSTEIN has received $340,260 in general promotional payments (such as consulting honoraria, meals, and speaking fees) and $165,230 in clinical research grants.

DR. STEPHANIE BERNSTEIN

MDReal-Time Hydrated

Specialty: Internal Medicine, Hematology & Oncology

Practice Location: WINCHESTER, MA 01890

NPI Number: 1396814265

LIFETIME INDUSTRY VALUE

$505,490

2021 – 2024 Cumulative

Conflict of Interest Analysis

Dr. BERNSTEIN is a verified Internal Medicine, Hematology & Oncology practitioner based in WINCHESTER, MA.

Between 2021 and 2024, Dr. BERNSTEIN had an overall industry promotional and research financial footprint of $505,490 as recorded in the federal CMS Open Payments database.

$340,260 was received in general payments, which include consultation fees, travel expenses, honoraria, and sponsored meals.
$165,230 was allocated to sponsored clinical trials and medical research activities.

Dr. BERNSTEIN's primary funding source is ACERTA PHARMA, which accounts for $224,305 (representing 44.4% of overall industry footprint).

Data coverage: 2021 – 2024 · Source: CMS Open Payments · CMS publishes each year's data around June 30 of the following year.

Payout Trend Over Time

General Payments

Research Funding

Top Funding Entities

Pharmaceutical & Device Manufacturers making direct payments

ACERTA PHARMA

Rank 1

$224,305

44.4%

JANSSEN RESEARCH & DEVELOPMENT

Rank 2

$104,045

20.6%

ASTRAZENECA UK LIMITED

Rank 3

$99,715

19.7%

Itemized Transaction Archives

Direct live query to Socrata CMS Open Payments API (Bypasses local DB)

Year:

2024

Filter < $250

Click "Load Live Logs" to query the federal Open Payments registry directly.

Frequently Asked Questions

Answers compiled using federal transparency disclosure records under the Sunshine Act.